interferon - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.95 [0.02, 50.33]< 10%1 study (1/-)51.0 %some concernnot evaluable moderatecrucial-
deaths 0.41 [0.18, 0.90]< 10%5 studies (5/-)98.7 %some concernnot evaluable moderatecrucial-
clinical improvement 2.36 [1.09, 5.12]> 10%1 study (1/-)98.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 8.77 [0.94, 81.67]> 10%1 study (1/-)97.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 2.17 [1.34, 3.51]> 10%3 studies (3/-)99.9 %some concernnot evaluable moderateimportant-
hospital discharge 3.44 [0.64, 18.49]> 10%1 study (1/-)92.4 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.75 [0.34, 1.69]< 10%3 studies (3/-)75.5 %some concernnot evaluable moderateimportant-
viral clearance 2.33 [0.55, 9.83]> 10%1 study (1/-)87.5 %some concernnot evaluable moderateimportant-
viral clearance by day 14 10.23 [1.12, 93.35]> 10%1 study (1/-)98.0 %some concernnot evaluable moderateimportant-
viral clearance by day 7 2.33 [0.55, 9.83]> 10%1 study (1/-)87.5 %some concernnot evaluable moderateimportant-
ICU admission 0.49 [0.24, 1.00]< 10%3 studies (3/-)97.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.95 [0.02, 50.33]< 10%1 study (1/-)51.0 %some concernnot evaluable moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %some concernnot evaluable moderateimportant-
adverse events 1.68 [0.47, 5.97]< 10%1 study (1/-)21.1 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.